Real World Evidence

As more and more novel medical products are brought to the market, how they perform in day-to-day clinical practice has become an important question. Clinicians, patients, family members, regulators, and payers are all eager to gain more insight into the utility of therapeutic and preventive regimens through Real World Evidence.

The Health Data Research Center (HDRC) at National Taiwan University is uniquely positioned in Taiwan to access and evaluate Real World Evidence of major medical products in Taiwan. Using the population-based National Health Insurance (NHI) data, which is linkable to cancer registry and mortality data, investigators and experienced analysts could adopt sophisticated observational research methods to address pertinent clinical and public health questions related to effectiveness, safety, and cost-effectiveness of medical products. As an integral member of the NTU community, the HDRC will strive to work with scientific investigators within NTU as well as global partners to provide high quality data and evidence about medical products in Taiwan.

Director 2016

From the Director

Thank you for visiting the HDRC website. In different sections of the website you will find important information about the data that we have access to and our research capability. We have extensive experience in carrying out high quality public domain research, obtaining funding from public sector funding source, and working with industry partners. Please let us know if you have any questions.

Management

Oct. 23, 2012 HDRC was established through a coregrant from the government.

  • First director:
    Shier-Chieg Huang (Jan. 01, 2012- Jun. 30, 2014)
  • Current director:
    K. Arnold Chan (Since Aug. 14, 2014)
    Dr. Chan is a physician epidemiologist with more than 20 years of global research experience in academia and private sector, primarily on evaluation of pharmaceutical agents and vaccines. He has served on the faculty at National Taiwan University and Harvard School of Public Health, and returned to his alma mater (National Taiwan University) in 2013.

    He has extensive experience in managing research organization and complex human research projects. In addition to scientific research, he has provided consulting input to Taiwan Food and Drug Administration and related health authority for more than 20 years. Dr. Chan has authored or co-authored more than 100 peer-reviewed articles on pharmacoepidemiology and clinical epidemiology. Along with Professor Abraham Hartzema and Professor Hugh Tilson, Dr. Chan co-edited one of the two widely used English textbook on pharmacoepidemiology.